Ucb SA
OTC:UCBJF

Watchlist Manager
Ucb SA Logo
Ucb SA
OTC:UCBJF
Watchlist
Price: 308.99 USD 1.47% Market Closed
Market Cap: $61.7B

Operating Margin

26.6%
Current
Improving
by 13.1%
vs 3-y average of 13.5%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
26.6%
=
Operating Income
€1.8B
/
Revenue
€6.8B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
26.6%
=
Operating Income
$1.8B
/
Revenue
€6.8B

Peer Comparison

Country Company Market Cap Operating
Margin
BE
Ucb SA
XBRU:UCB
49.5B EUR
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
528.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
221.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
267.9B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.6B USD
Loading...

Market Distribution

Higher than 70% of companies in Belgium
Percentile
70th
Based on 476 companies
70th percentile
26.6%
Low
-11 800% — 4.9%
Typical Range
4.9% — 26.6%
High
26.6% — 45 050%
Distribution Statistics
Belgium
Min -11 800%
30th Percentile 4.9%
Median 11%
70th Percentile 26.6%
Max 45 050%

Ucb SA
Glance View

Market Cap
61.7B USD
Industry
Pharmaceuticals

UCB SA, a Belgian multinational biopharmaceutical company, stands at the forefront of innovation in the medical field, committed to creating value by discovering new ways to treat severe diseases. Founded in 1928, UCB has transformed over the decades from its initial focus in chemicals to pioneering developments in advanced therapeutics targeting central nervous system disorders and immunology. Anchored by a robust research pipeline and a keen focus on rare diseases and specialty care, UCB has established a strong presence globally, reflecting its strategic pivot toward patient-centric approaches. With primary research facilities stationed in Braine-l'Alleud, Belgium, and Slough, UK, the company's scientific endeavors are bolstered by collaborations with research institutions worldwide, fostering an environment ripe for breakthrough discoveries. Financially, UCB's revenue streams are predominantly derived from its established portfolio of blockbuster drugs, such as Cimzia, Vimpat, and Keppra, which serve as critical lifelines for patients dealing with autoimmune diseases, epilepsy, and other chronic conditions. The company thrives on a dynamic business model that combines in-house scientific research with strategic partnerships and acquisitions to enhance its competitive edge. This synergy not only facilitates sustained growth in its core markets but also drives expansion into emerging ones, underscoring its global reach. By reinvesting substantial portions of its earnings into research and development, UCB ensures a steady pipeline of new products, thereby maintaining its stature in the highly competitive biopharmaceutical landscape. Through such strategic maneuvers, UCB aligns its operations with the overarching goal of delivering transformative therapies that improve the quality of life for patients around the world.

UCBJF Intrinsic Value
287.26 USD
Overvaluation 7%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
26.6%
=
Operating Income
€1.8B
/
Revenue
€6.8B
What is Ucb SA's current Operating Margin?

The current Operating Margin for Ucb SA is 26.6%, which is above its 3-year median of 13.5%.

How has Operating Margin changed over time?

Over the last 3 years, Ucb SA’s Operating Margin has increased from 19.8% to 26.6%. During this period, it reached a low of 9% on Jun 30, 2023 and a high of 26.6% on Jun 30, 2025.

Back to Top